Ce guide clinique offre des recommandations de traitements non pharmacologiques pour lesdésordres de tic. Nous avons mené une recherche systématique dans la littérature d'essais cliniques sur le traitement des tics. Une revue fondée sur des données probantes (incluant 30 études) et 3 études sur les interventions comportementales, 3 études sur la stimulation cérébrale profonde (SCP), et 3 études sur la stimulation magnétique transcranienne (SMT) satisfaisaient à nos critères d'inclusion. D'après ces données probantes, nous avons fait des recommandations fermes pour l'utilisation de la thérapie de renversement d'habitudes, et de l'exposition et prévention de la réponse,
This clinical guideline provides recommendations for nonpharmacological treatments for tic disorders. We conducted a systematic literature search for clinical trials on the treatment of tics. One evidence-based review (including 30 studies) and 3 studies on behavioural interventions, 3 studies on deep brain stimulation (DBS), and 3 studies on transcranial magnetic stimulation (TMS) met our inclusion criteria. Based on this evidence, we have made strong recommendations for the use of habit reversal therapy and exposure and response prevention, preferably embedded within a supportive, psychoeducational program, and with the option to combine either of these approaches with pharmacotherapy. Although evidence exists for the efficacy of DBS, the quality of this evidence is poor and the risks and burdens of the procedure are finely balanced with the perceived benefits. Our recommendation is that this intervention continues to be considered an experimental treatment for severe, medically refractory tics that have imposed severe limitations on quality of life. We recommend that the procedure should only be performed within the context of research studies and by physicians expert in DBS programming and in the management of tics. There is no evidence to support the use of TMS in the treatment of tics. However, the procedure is associated with a low rate of known complications and could continue to be evaluated within research protocols. The recommendations we provide are based on current knowledge, and further studies may result in their revision in future.
T he tic disorders constitute a spectrum of heritable neuropsychiatric conditions characterized by the presence of tics that begin in childhood, typically peak in severity just before adolescence, and improve by adulthood. 1 Education is the only treatment needed for most patients with tics; however, for patients with more severe or disabling tics, medical or behavioural interventions may be offered. Historically, the mainstay of treatment for severe tics has been antipsychotics. While the clinical efficacy of these agents is established, they often have undesirable side effects. An attractive alternative to pharmacotherapy are behavioural interventions, which require an investment of time but are generally free of side effects. Behavioural interventions to treat tics have a long history, but during the last decade a growing interest in this approach has led to the completion of several RCTs in this area. During a similar period, DBS has been evaluated to treat people with the most severe and medically intractable tics. More recently still, the efficacy of rTMS has been studied as another alternative to pharmacotherapy for tics.
Here, we review the evidence for the efficacy of the nonpharmacological treatments for tics and provide evidencebased recommendations for their use. This guideline attempts to address 2 essential questions: Which nonpharmacological interventions are effective in the treatment of tics? What are the benefits and harms of these therapies?
Methods
The methodology for the systematic review, consensus group meeting, and generation of treatment recommendations are described in detail in the companion In Review article on the pharmacotherapy of tic disorders. 2 Cook 
Results

Behavioural Interventions for Tics
Highlights
• Habit reversal therapy and exposure and response prevention are strongly recommended for the treatment of tics.
• DBS should be considered an experimental treatment for severe, medically refractory tics that have imposed severe limitations on quality of life.
• There is no evidence to support the use of TMS for the treatment of tics.
préférablement encadrées dans un programme psycho-éducatif de soutien, et avec l'option de combiner l'une de ces deux approches avec la pharmacothérapie. Bien que des données probantes appuient l'efficacité de la SCP, la qualité de ces données est médiocre et les risques et les fardeaux associés à la procédure sont en équilibre délicat avec les avantages perçus. Notre recommandation est que cette intervention soit encore considérée comme étant un traitement expérimental pour les tics graves, médicalement réfractaires qui imposent des limites importantes à la qualité de vie. Nous recommandons que l'intervention ne soit pratiquée que dans le contexte d'études de recherche et par des médecins experts de la programmation SCP et de la prise en charge des tics. Aucune donnée probante ne soutient l'utilisation de la SMT dans le traitement des tics. Toutefois, l'intervention est associée à un faible taux de complications connues et pourrait continuer à être évaluée dans le cadre de protocoles de recherche. Les recommandations que nous fournissons sont basées sur les connaissances actuelles, et d'autres études pourraient résulter de leur révision à l'avenir.
results that were promising and met certain thresholds of empirical support, but that still needed independent replication with a larger sample size or with a sufficient control group.
In total, 30 studies were included in Cook and Blacher's analysis, 3 representing a total of 221 participants, aged 7 to 66 years. Only studies evaluating HRT and ERP met criteria for well-established or probably efficacious treatments for tics. The remaining 4 types of psychological treatments did not fulfill criteria for consideration as well established or probably efficacious.
HRT attempts to break a postulated cycle of negative reinforcement that occurs when the performance of a tic reduces the unpleasant urge to make it. The protocol for HRT first emphasizes awareness of premonitory sensations or urges, and then trains the person to perform a competing voluntary movement that is physically incompatible with the performance of the tic, typically until the urge to perform the tic goes away.
Twenty HRT studies were included in Cook and Blacher's review, 3 including 6 RCTs and 14 rigorous single-case experimental designs. In all but one study, most participants demonstrated significant improvement in tics. Based on APA criteria, Cook and Blacher 3 concluded that HRT was a well-established treatment.
The rationale for ERP is similarly based on learning theory, which proposes that tics occur as a conditioned response to unpleasant internal stimuli (urge). When such stimuli recur over time, the simple association between the sensation and the tic is strengthened. Instead of using competing responses, ERP attempts to break this association by asking the patient to suppress tics for prolonged periods through the use of various cognitive tools. In theory, this teaches the patient to habituate to the sensation, that is, learn to tolerate the unpleasant sensation without responding to it, which may lessen the urge to perform the tic.
Only a single study of ERP was included in the review. Verdellen et al 4 compared ERP to HRT in 43 participants, aged 7 to 55 years. Participants were randomized to 12 weekly sessions of ERP or 10 weekly sessions of HRT. Total tic severity on the YGTSS improved significantly between baseline and end point in both treatment groups, with no significant differences demonstrated between treatments. Based on APA criteria, Cook and Blacher 3 concluded that ERP satisfied the requirements necessary for a probably efficacious treatment.
Since publication of the Cook and Blacher 3 evidence-based review, 3 additional studies on HRT for tics have been published (Table 1 ). Piacentini et al 5 performed a goodquality RCT on HRT, compared with supportive therapy, for the treatment of tics in 126 youth with tic disorders. Comorbid conditions within this sample were considerable, and 36.5% of the sample were already on a stable dose of medication for their tics. Subjects were randomized to 8 sessions of therapy during 10 weeks. Total tic severity on the YGTSS decreased from 24.7 points at baseline to 17.1 points at week 10 with HRT, compared with a decrease from 24.6 points to 21.1 points with supportive therapy (P < 0.001). Among children receiving HRT, 52.5% were rated as very much improved or much improved on the Clinical Global Impressions-Improvement Scale, compared with 18.5% of children receiving supportive therapy (P < 0.001). One participant receiving HRT and 4 participants receiving supportive therapy reported worsening of tics. No adverse events related to the study were encountered. Notably, 86.9% of participants receiving HRT remained treatment responders, even at 6 months follow-up.
Deckersbach et al 6 conducted an unblinded RCT of HRT, compared with supportive psychotherapy, in 30 adults with TS. Subjects received 14 sessions of therapy during a 5-month period. HRT decreased YGTSS total tic scores from 29.3 points at baseline to 18.3 points posttreatment, compared with supportive psychotherapy, which decreased YGTSS total tic scores from 27.7 points to 26.8 points (P = 0.001). Ten of 15 subjects receiving HRT were classified as much improved or very much improved at the end of treatment, in contrast to 2 of 15 subjects in the supportive psychotherapy group (P = 0.008).
Himle et al 7 conducted an open pilot study of 3 children receiving HRT for tics delivered via video conference. Improvements in 2 of the 3 children were comparable to results obtained in previous RCTs of face-to-face HRT, leading the authors to suggest that video conference delivery may be a promising method for disseminating HRT to areas where regional expertise or services are lacking.
Recommendation Grade for HRT: Strong Recommendation, High-Quality Evidence. Recommendation Grade for ERP:
Strong Recommendation, Low-Quality Evidence. Based on current evidence, we recommend both HRT and ERP as first-line behavioural treatments, both for children and for adults. It should be noted that past concerns of tic suppression resulting in a so-called rebound effect have been more recently debunked. 8, 9 Other behavioural treatments identified in the literature have insufficient evidence to recommend their use. Relaxation training in isolation lacks a sufficient evidence base to be considered a stand-alone efficacious treatment 10, 11 but is often incorporated into HRT protocols. 12 If both HRT and ERP are available, HRT would be the preferred mode of therapy, as a substantially larger base of evidence supports its use. However, HRT requires a skilled therapist, who may not be available at all centres. Conversely, as ERP is an established technique for the treatment of obsessive-compulsive disorder, it is possible that in centres where HRT is unavailable, therapists with expertise in ERP may more easily be able to provide treatment using this alternative modality. One important caveat is that behavioural therapies are unlikely to be helpful in very young children (aged 9 years and younger), or in children with severe, untreated attention-deficit 
DBS for the Treatment of Tics
To date, 25 published studies, representing data from 69 patients, have reported on the efficacy of DBS in the treatment of TS refractory to medical and behavioural treatments. With the exception of one large-scale case series from Italy, 14 most of these studies have reported results of stimulation in individual patients. RCTs with large numbers of patients are lacking. Among the 69 patients reported to date, improvement in tics have been reported in 65 (93.7%), and in some instances associated comorbidities have improved as well. DBS has almost certainly been performed in many more patients than the numbers reported to date, leaving open the possibility of a substantial reporting bias. Attempts to interpret the existing results are further complicated by the large number of different structures that have been targeted with DBS, which, depending on the specific stereotactic coordinates and terminology reported, may extend to 10. The rational for the choice of all targeted structures to date is that all belong to the ventro striatal-thalamo-cortical circuits that are thought dysfunctional in TS. The 2 areas most frequently stimulated have been regions of the CM nucleus of the thalamus and the GPi of the striatum.
For our evidence-based analysis, only 3 studies met inclusion criteria ( At the end of the blinded ON period, the authors reported a 37% mean reduction in YGTSS (P = 0.05) and a significant reduction in total video tic counts (P = 0.05), compared with the end of the blinded OFF period, but no significant difference in the MRVRS. At 1-year follow-up, unblinded, a 49% reduction in the YGTSS (P = 0.03) and a 35% reduction in the MRVRS (P = 0.05) was documented, compared with the preoperative assessment. No significant effects on behavioural or mood symptoms were observed at the group level. At 1 year, patients took significantly more time to complete the Stroop colour-word test, a measure of selective attention and response inhibition.
The authors reported numerous significant adverse events. All patients reported subjective gaze impairments and reduced energy sufficient to restrict daily activity. Notably, one patient, during the year following electrode implantation, suffered an unexplained syndrome of apathy, gait disturbance, and progressive cerebral atrophy. One patient suffered a small hemorrhage ventral to the tip of one of the stimulating electrodes and another patient from a skin infection at the site of the pulse generator.
Welter et al 16 performed a fair-quality crossover RCT of 3 patients treated with bilateral DBS of the CM-Pf complex and GPi. They evaluated patients 1 month before surgery and 2 months after surgery, all without stimulation. Patients were then stimulated with identical parameters (60 µsecs and 130 Hz) and evaluated monthly during 5-day hospitalization periods, with the following double-blinded, randomized protocols: bilateral thalamic stimulation for 2 months; bilateral GPi stimulation for 2 months; bilateral thalamic plus GPi stimulation for 2 months; and sham stimulation (no current) for 2 months. This period of blinded evaluation was then followed by an open-label follow-up performed at postoperative months 60, 33, and 20 for patients 1 to 3, respectively.
The authors reported the best improvements with ventromedial GPi stimulation: 65%, 96%, and 74% reductions in total YGTSS for patients 1 to 3, respectively. This is compared with the best effects of CM-Pf thalamic stimulation, which produced reductions of 64%, 30%, and 40%. Combined thalamic-GPi stimulation did not improve tic reduction further.
The authors also commented on the stability of treatment effects. For patients 1 and 3, the effects remained stable or improved during 2 months. For patient 2, the effect decreased or disappeared at 2 months. At long-term follow-up, patient 2 required monthly adjustments in stimulation parameters to maintain efficacy. The authors noted that psychiatric symptoms tended to improve with stimulation, and cognition remained stable.
Numerous adverse effects were noted. With thalamic stimulation, all 3 patients reported decreased libido as well as transient paresthesias, particularly in arms and around the mouth. For GPi stimulation, 2 patients reported transient lethargy, nausea, and vertigo, and 1 patient reported anxiety. The authors reported in the ON/ON state a significant 4.2 point reduction (P = 0.03) in the MRVRS and a significant raw motor tic count reduction of 53% (P = 0.02).
The authors also noted at the start of the open-label phase a 18 Our recommendation is that the procedure should be reserved for treatment within research protocols and performed by physicians expert in DBS programming and in the management of TS. Stimulation of the thalamus (CM-Pf) and the GPi have also been associated with significant adverse events, and patients should be counselled carefully about complications before proceeding with surgery.
TMS for the Treatment of Tics
The effects of TMS have also been evaluated for TS. The intervention is based on the principal of electromagnetic induction, whereby a brief magnetic field delivered at the surface of the scalp induces a current along the surface of the cortex that can alter the activation of cortical neurons and interneurons. Studies using paired pulses of TMS to examine intrinsic inhibition or excitation of the cortex have found a general deficiency of inhibition in the motor cortices of patients with TS. 19 Simultaneously, rTMS has been shown to have varying effects on the function underlying the motor cortex, possibly as a function of the frequency of application, with long slow trains of rTMS temporarily reducing corticospinal excitability 20 and faster trains increasing it. 21, 22 Therefore, numerous studies have applied rTMS protocols to patients with TS, attempting to normalize the presumed cortical hyperexcitability with the goal of reducing tics.
We identified a total of 3 studies 23-25 evaluating the effects of rTMS in adults with TS that satisfied our inclusion criteria (online eTable 3). None of these studies found a significant change in tic symptoms with rTMS.
Recommendation Grade for rTMS in Adults: Category X1, Insufficient Evidence to Make a Formal Recommendation.
Recommendation Grade for rTMS in Children: Not Recommended. On review of the existing studies, our recommendation is that there is no good evidence to support the use of rTMS in the treatment of TS. However the procedure is associated with a low rate of known complications, and should continue to be reserved for evaluation within research protocols.
Discussion
Based on the current available evidence, we have made strong recommendations for HRT and ERP, preferably embedded within a supportive, psycho-educational program, and with the option of combining either of these approaches with drug treatment. The quality of the evidence for the use of DBS in the treatment of tics is poor, and the risks and burdens of the procedure are finely balanced with the perceived benefits. Our recommendation is that this intervention should continue to be considered as an experimental treatment in adults for severe, medically refractory tics that have imposed severe limitations on quality of life. We feel that the procedure should only be performed within the context of research studies and by physicians expert in DBS programming and in the management of TS. There is no evidence to support the use of rTMS in the treatment of TS. However, the treatment is associated with a low rate of known complications and should continue to be evaluated within research protocols. These recommendations are based on current knowledge, and further studies may result in their revision in future.
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